Biogen to buy Pfizer's neurology drug in deal nearing $600 million

(Reuters) – Biogen Inc said on Monday it would buy Pfizer Inc’s experimental treatment for a symptom associated with schizophrenia in a deal that could near $600 million and mark its foray into the emerging market for neuropsychiatry.


Source: Reuters Health

Leave a Reply

Your email address will not be published. Required fields are marked *